Table 1 Patient characteristics of the 57 patients included in the present study.
Erlotinib | Chemotherapy | Total (N = 57) | P Value Test | |
|---|---|---|---|---|
(N = 29) | (N = 28) | |||
Sex N(%) | ||||
Female | 19 (65.5) | 21 (75.0) | 40 (70.2) | Chi-Square: 0.4340 |
Male | 10 (34.5) | 7 (25.0) | 17 (29.8) | |
Age N(%) | ||||
<65 years | 15 (51.7) | 12 (42.9) | 27 (47.4) | Chi-Square: 0.5027 |
> = 65 years | 14 (48.3) | 16 (57.1) | 30 (52.6) | |
Smoking status N(%) | ||||
Never smoked | 15 (51.7) | 19 (67.9) | 34 (59.7) | Fisher: 0.2416 |
Former smoker | 12 (41.4) | 6 (21.4) | 18 (31.6) | |
Current smoker | 2 (6.9) | 3 (10.7) | 5 (8.8) | |
ECOG PS* N(%) | ||||
0 | 9 (31.0) | 11 (39.3) | 20 (35.1) | Fisher: 0.5693 |
1 | 15 (51.7) | 15 (53.6) | 30 (52.6) | |
2 | 5 (17.2) | 2 (7.1) | 7 (12.3) | |
Histologic Diagnosis N(%) | ||||
Adenocarcinoma | 28 (96.6) | 24 (85.7) | 52 (91.2) | Fisher: 0.1086 |
Bronchioalveolar adenocarcinoma | 0 (0.0) | 1 (3.6) | 1 (1.8) | |
Large-cell carcinoma | 1 (3.5) | 0 (0.0) | 1 (1.8) | |
Other | 0 (0.0) | 3 (10.7) | 3 (5.3) | |
Clinical Stage N(%) | ||||
IIIB (malignant effusion) | 4 (13.8) | 1 (3.6) | 5 (8.8) | Fisher: 0.3516 |
IV | 24 (82.8) | 27 (96.4) | 51 (89.5) | |
Unknown | 1 (3.5) | 0 (0.0) | 1 (1.8) | |
Bone metastasis N(%) | ||||
Yes | 7 (24.1) | 9 (32.1) | 16 (28.1) | Chi-Square: 0.5013 |
No | 22 (75.9) | 19 (67.9) | 41 (71.9) | |
Brain metastasis N(%) | ||||
Yes | 4 (13.8) | 4 (14.3) | 8 (14.0) | Fisher: 1.0000 |
No | 25 (86.2) | 24 (85.7) | 49 (86.0) | |
Type of EGFR mutation N(%) | ||||
del19 | 18 (62.1) | 19 (67.9) | 37 (64.9) | Chi-Square: 0.6471 |
L858R | 11 (37.9) | 9 (32.1) | 20 (35.1) | |
